In early breast cancer, the FDA-approved and CE-marked Prosigna assay provides a risk of recurrence (ROR) score that predicts the prognosis for patients with hormone-receptor-positive, HER2-negative tumors. This evidence concerns the gene ERBB2 and breast carcinoma.